Predictive value of immune-modified Glasgow prognostic score in patients with head and neck squamous cell carcinoma treated with nivolumab
The immune-modified Glasgow Prognostic Score proves valuable for predicting prognosis in patients with head and neck squamous cell carcinoma undergoing nivolumab treatment, particularly excelling in identifying individuals unlikely to respond to nivolumab.
Authors
- Bunya Kuze
- Masato Takiwaki
- Hiroki Takahashi (ORCID: https://orcid.org/0000-0003-0528-0446)
- Hiromichi Shirato
- Takenori Ogawa (ORCID: https://orcid.org/0000-0003-1556-7328)
- Hirofumi Shibata (ORCID: https://orcid.org/0000-0002-7104-9456)
- S. Tanahasi
- Masami Ohnishi
- Kosuke Terazawa (ORCID: https://orcid.org/0000-0002-0033-652X)
- Takanori Wakaoka
- Toshimitsu Ohashi (ORCID: https://orcid.org/0000-0003-2347-6709)
- Keisuke Mizuta
- Nansei Yamada
Institutions
- Koujin Hospital (JP)
- Gifu Municipal Hospital (JP)
- Ishikiriseiki Hospital (JP)
- Ichinomiya Municipal City Hospital (JP)
- Ichinomiya Kenshin College (JP)
- Sapporo Kosei General Hospital (JP)
- Ogaki Municipal Hospital (JP)
- Saitama International Medical Center (JP)
- Gifu Prefectural General Medical Center (JP)
- Takayama Red Cross Hospital (JP)
- Gifu University (JP)
Publication Details
- Journal
- The Journal of Laryngology & Otology
- Published
- 2025-07-14
- DOI
- https://doi.org/10.1017/s0022215125102612
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00